Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epanutin

- PMLiVE

Pfizer launches chronic pain forum

Twitter style comments are used to help patients describe their conditions

- PMLiVE

Succinct forms market access partnership with Royal Marsden

Agency aims is to tackle non-financial issues relating to new medicines

- PMLiVE

NICE metrics flawed and should not be used, says EU study

ECHOUTCOME criticises used of quality adjusted life years in HTAs

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

Covance collaborates with UK hospital on early clinical research

Says agreement will provide quicker access to patients for phase I trials

- PMLiVE

NICE consults on what makes good social care

Citizens Council gives views as UK agency prepares to expand its remit

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

Guidance published encouraging NHS to adopt social media

Social media is central to the effectiveness of the NHS, says NHS Employers organisation.

- PMLiVE

IQWiG finds some value in Pfizer’s Inlyta

Cost effectiveness body decides cancer drug has benefits over Bayer's Nexavar

UK outlines pipedream of a paperless health service

Health secretary issues empty 'challenge' for NHS to make better use of IT

- PMLiVE

UK inactivity on value-based pricing plan damaging, say MPs

Health Committee report also highlights needs to address end of the cancer drugs fund

- PMLiVE

Pfizer enters ADHD market with Quillivant XR launch

Gained rights last November as part of NextWave acquisition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links